Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Video

Dr Finn reviews the results from the Leap-002 study which evaluates the use of lenvatinib with pembrolizumab in the front-line setting for patients with advanced hepatocellular carcinoma.

Background

The global, randomized, double-blind, Ph3 LEAP-002 study (NCT03713593) evaluated the efficacy and safety of lenvatinib + pembrolizumab (lenva + pembro) vs lenvatinib (lenva) + placebo as 1L therapy for advanced hepatocellular carcinoma (aHCC).

Methods

  1. Eligible pts with aHCC were randomized 1:1 to lenvatinib (8 mg/day if BW<60 kg or 12 mg/day if BW≥60 kg) plus pembrolizumab (200 mg IV Q3W) or lenvatinib plus placebo.
  2. Dual primary endpoints OS and PFS (per RECIST 1.1 by BICR) were assessed using the stratified log-rank test. ORR (per RECIST 1.1 by BICR) was a key secondary endpoint.
  3. The protocol specified 2 interim analyses (IAs) and a final analysis (FA) for OS. Prespecified efficacy boundaries were one-sided P = 0.002 for PFS at IA1 (prespecified final PFS analysis) and 0.0185 for OS at FA.

Results

  1. 794 pts were randomized (lenvatinib+ pembrolizumab, 395; lenvatinib, 399).
  2. At FA (data cutoff 21 June 2022; median follow-up 32.1 months), 534 OS events had occurred and 36 pts (9.1%) in the lenvatinib + pembrolizumab arm and 24 pts (6.1%) in the lenvatinib arm remained on study treatment.
  3. The median OS with lenvatinib + pembrolizumab was 21.2 months vs 19.0 months with lenvatinib, and the HR was 0.840 (95% CI: 0.708-0.997, P=0.0227).
  4. HR for PFS at IA1 (data cutoff 5 April 2021) was 0.867 (95% CI: 0.734-1.024, P=0.0466,)
  5. ORR at FA was 26.1% for lenvatinib + pembrolizumab vs 17.5% for lenvatinib.
  6. Grade 3-5 treatment-related adverse events (TRAEs) were 62.5% in the lenvatinib + pembrolizumab arm and 57.5% in the lenvatinib arm (grade 5 TRAEs, 1.0% vs 0.8%).
  7. Post-study systemic anti-cancer treatments were used in 44.1% vs 52.1% of pts, in each arm, respectively.

Conclusions

  • LEAP-002 primary endpoints of OS (at FA) and PFS (at IA1) did not meet pre-specified statistical significance.
  • The combination of lenvatinib+ pembrolizumab achieved the longest median OS ever reported in 1L HCC Ph3 studies (21.2 months) with no new safety signals observed.
  • The median OS of 19.0 months with lenvatinib monotherapy supports its role as a standard of care in 1L aHCC.

Finn RS, Kudo M, Merle P et al. Primary Results from the Phase 3 LEAP-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma Abstract presented at: 2022 European Society of Medical Oncology, September 9-13, 2022; Paris, France & Online. Abstract # LBA34 https://oncologypro.esmo.org/meeting-resources/esmo-congress/primary-results-from-the-phase-iii-leap-002-study-lenvatinib-plus-pembrolizumab-versus-lenvatinib-as-first-line-1l-therapy-for-advanced-hepatoce

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Yelena Y. Janjigian, MD, an expert on gastrointestinal cancer
Guru P. Sonpavde, MD, an expert on urothelial carcinoma
Related Content